Intelligent Bio Solutions (INBS) has entered a partnership with Syrma Johari to expand the production of its intelligent fingerprint drug screening reader.
The partnership is anticipated to generate financial and operational benefits for INBS, including annual production cost savings of over 40%, and an estimated 20 percentage point improvement in gross margin over the prior manufacturing set-up.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Syrma Johari’s production capability is about four times greater than INBS existing capacity, enabling the latter to accommodate anticipated growth as it broadens commercial operations.
The partnership supports INBS’ strategy to diversify its manufacturing base, enhancing supply chain resilience and reducing dependence on a single supplier.
The expanded capacity will create flexibility and ensure continuity as the company prepares for rising demand in multiple regions and prepares for entry into the US in 2026.
Syrma Johari has over 45 years of experience in designing and producing regulated medical technology, operating 14 manufacturing sites and four design and innovation centres across Europe, US, and India, with a combined plant area of more than 1.1 million ft2.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIts regulatory expertise supports INBS’ expansion and compliance efforts in Canada, Europe, the US, Asia-Pacific, and the UK. The company offers end-to-end quality systems and regulatory documentation required in these key jurisdictions.
Intelligent Bio Solutions global quality and operations vice-president Callistus Sequeira said: “Partnering with Syrma Johari is a strategically significant milestone for our business. Its global footprint, manufacturing excellence, and proven track record in regulated medical devices make it an outstanding partner as we scale production of our drug screening reader.
“This collaboration strengthens our supply chain, supports future growth, and enhances our ability to deliver reliable, high-quality products to customers around the world.”
